FOR PHARMACISTS · SCIENTIFIC COLLECTION 10.0310 monographs · 36 SOPs · 22 forms
Sikaliascompounding.grSikalias Greek Formulary
Home / Allergens / Pistachio — syrup-matrix development dossier · ALG-001

ALG-001 / 3.0

Pistachio — syrup-matrix development dossier

Final scientific review of the published technical example. The decision is explicit: publish as a development and evidence dossier, without an executable clinical recipe or numerical BUD. Results for the actual batch, matrix and package have not been supplied.

Collection and scientific editing: Stasinos Chr. SikaliasContent edition: 3.0Record editorial review date: 2026-10-14

Download bilingual PDFJSON

Raw-material identity

Record Pistacia vera, origin, lot, nut fraction, thermal processing, milling, moisture and additives or other-nut contamination. Supplier or roasting changes require new comparison. Nutrition-label protein does not establish this finished preparation’s concentration.

Syrup matrix and process

Record sugars, water, final volume/mass, viscosity and dissolved/suspended fractions. Assess material retained on filters and vessels. Heating can alter the protein profile and does not demonstrate allergen inactivation. Sampling before and after critical steps must address a defined analytical question.

Protein and actual withdrawal

Define the analyte linked to the clinical order. Establish method suitability in the sugar matrix, recovery and concentration range. Assess the dosing device, smallest withdrawal and within-container uniformity through use. Do not derive mg protein/mL solely from starting nut mass.

Clinical evidence and transfer limits

NUT CRACKER studied cashew immunotherapy and reported cross-desensitisation in patients with confirmed co-existing pistachio allergy. Sensitisation on a diagnostic test alone does not establish clinical allergy. The study did not assess this syrup, extraction, filtration or shelf life.

Use decision

Require a complete specialist order, confirmed strength, uniformity, microbiological quality, preservation, packaging and stability evidence. Without those data, no clinically executable recipe or numerical use-by period is assigned. OIT-001 through OIT-008 and F-008/F-009 define the dossier structure.

Additional processing evidence

The laboratory study by Shwe Yee and colleagues (2024) showed that wet thermal processing changes extractable protein, protein profiles and antibody binding in cashew/pistachio. This supports assessment before and after processing; it does not establish clinical safety, recovery in sugar syrup or BUD. Characterise the aqueous fraction and residue separately whenever the process separates them.

Total protein and potency

The assumption that starting nut mass or total-protein measurement establishes allergenic potency is rejected. EMA/161669/2025, effective 1 January 2026, calls for suitable potency measurement where technically feasible and a justified combined strategy otherwise. For a local product, separately document dose basis and justification of selected analytes, suitable reference materials and matrix suitability. These are adapted industrial-quality principles, not an independent compounding authorisation.

Specific water-activity evidence

Measure aw in the finished syrup matrix and relevant dilutions using a calibrated instrument, controlled temperature and documented equilibration. Record result, method, temperature, sample and batch. The name syrup, sugar percentage and vehicle-only aw do not establish product aw. The USP classification value of 0.60 does not approve a BUD, and the food-regulatory value of 0.85 is not a pharmaceutical threshold. Low aw does not establish retention of protein/potency.

Sources and references

  1. EMA — Guideline on Allergen Products: Production and Quality IssuesEMEA/CHMP/BWP/304831/2007; adopted 20 November 2008; effective 20 May 2009; remains current effective quality version on EMASections 2, 4.1.1, 4.2.4.4, 4.4.3–4.4.5; document pp. 4–13Industrial biological-allergen quality guidance; principles adapted explicitly, not a compounding authorisation or a food-OIT recipe2026-10-14
  2. Santos AF et al. EAACI guidelines on the management of IgE-mediated food allergyAllergy. 2025;80:14–36; online 2024Recommendations 8, 9, 12 and 13; desensitisation versus remission/continued treatmentSpecialist clinical recommendations; not stability evidence for local syrups or suspensions2026-10-14
  3. Elizur A et al. Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (NUT CRACKER study)Allergy. 2022;77:1863–1872Abstract, methods and results; PMID 35000223; DOI 10.1111/all.15212Cashew OIT cohort and pistachio cross-desensitisation; no pistachio syrup or peanut suspension stability data2026-10-14
  4. PIC/S — Guide to Good Practices for the Preparation of Medicinal Products in Healthcare EstablishmentsPE 010-4, 1 March 2014Chapters 1–9; Annex 2 (nonsterile liquids, creams, ointments)Professional quality-system framework; not automatic national legal adoption or certification2026-10-14
  5. EMA — Guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populationsEMA/161669/2025; adopted 10 June 2025; effective 1 January 2026Sections 2, 4 and 4.1 (Type I allergy quality aspects); pp. 4–6; section 8.4 for food-allergy endpointsIndustrial allergen development and quality guidance; complements 2008 guideline. Section 4.2 Type IV patch-test exceptions are not transferred to food OIT.2026-10-14
  6. Shwe Yee N et al. Development of Cashew and Pistachio Ladders through a Food-Processing ApproachFoods. 2024;13(21):3440Abstract and figures; DOI 10.3390/foods13213440Primary laboratory processing/extraction and antibody-binding work; no local syrup validation, clinical dose-equivalence factor or BUD.2026-10-14
  7. USP — Compounding Standards and Beyond-Use Dates, 2022 updateNovember 2022, published by USP; public copy hosted by Mississippi Boardpp. 1–2; nonsterile tableRisk-based default categories; not product-specific stability or Greek law2026-10-14
  8. FDA — Water Activity (aw) in FoodsInspection Technical Guide 39, 16 April 1984; website copy accessed 2026-09-12Definition; sorption behaviour; measurement equipmentMetrological principles only. Food regulatory thresholds and old instrument recommendations are not pharmaceutical BUD rules2026-10-14